Related Experiment Video
Updated: Jun 30, 2026
12:03
Expression, Isolation, and Purification of Soluble and Insoluble Biotinylated Proteins for Nerve Tissue Regeneration
Published on: January 22, 2014
[Human serum albumin: gene-technological possibilities].
1Aarhus Universitet, Institut for Medicinsk Biokemi, Arhus C. ukh@biokemi.au.dk
Ugeskrift for Laeger
|September 24, 2008
Summary
Gene technology enables the creation of recombinant human serum albumin for clinical applications. This advancement allows for tailored albumins with enhanced properties for drug targeting and improved therapeutic bioavailability.
Area of Science:
- Biotechnology
- Molecular Biology
- Protein Engineering
Context:
- Human serum albumin (HSA) is a crucial protein with diverse physiological roles.
- Current limitations in HSA's therapeutic applications exist.
- Advancements in gene technology offer new possibilities for protein modification.
Purpose:
- To explore the potential of gene technology in creating novel human serum albumin variants.
- To outline the applications of engineered albumins in medicine and drug delivery.
Summary:
- Recombinant DNA technology facilitates the production of human serum albumin (HSA) with modified characteristics.
- Engineered HSA isoforms can exhibit enhanced binding affinities for use as antidotes or for targeted drug delivery.
- Albumin-ligand complexes and albumin fusions can be developed to improve drug bioavailability and create patient-specific therapies.
Impact:
- This technology promises to revolutionize therapeutic protein development.
- Engineered albumins offer potential for more effective and personalized medical treatments.
- Future applications may include tailored albumin therapies for specific patient populations.
Related Concept Videos
01:09Recombinant DNA
Overview
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:20The Central Dogma
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
00:49What is Genetic Engineering?
Overview
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...